|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.96 EUR | -2.36% |
|
-0.66% | -4.92% |
| Feb. 18 | Mirova Holds Less Than 5% of Voting Rights in MedinCell | |
| Feb. 17 | Mirova Falls Below 5% Voting Rights Threshold in MedinCell |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 8.19M | 4.09M | 9.89M | 9.03M | 25.42M | |||||
Other Revenues, Total | 3.59M | 1K | 3.77M | 2.91M | 2.31M | |||||
Total Revenues | 11.78M | 4.09M | 13.66M | 11.94M | 27.73M | |||||
Cost of Goods Sold, Total | - | - | - | - | - | |||||
Gross Profit | 11.78M | 4.09M | 13.66M | 11.94M | 27.73M | |||||
Selling General & Admin Expenses, Total | 7.58M | 8.49M | 9.72M | 11.79M | 14.18M | |||||
R&D Expenses | 19.56M | 23.58M | 27.92M | 21.05M | 24.31M | |||||
Other Operating Expenses | 5K | 81K | 44K | 40K | - | |||||
Other Operating Expenses, Total | 27.14M | 32.15M | 37.68M | 32.88M | 38.49M | |||||
Operating Income | -15.37M | -28.06M | -24.02M | -20.94M | -10.76M | |||||
Interest Expense, Total | -3.58M | -1.84M | -3.93M | -4.62M | -5.09M | |||||
Interest And Investment Income | 40K | 46K | 41K | 553K | 1.4M | |||||
Net Interest Expenses | -3.54M | -1.8M | -3.89M | -4.06M | -3.69M | |||||
Currency Exchange Gains (Loss) | -226K | 829K | 1.17M | 135K | -230K | |||||
Other Non Operating Income (Expenses) | 356K | -23K | -5.2M | -44K | -3.52M | |||||
EBT, Excl. Unusual Items | -18.78M | -29.05M | -31.95M | -24.91M | -18.2M | |||||
Gain (Loss) On Sale Of Investments | - | - | -37K | - | - | |||||
Gain (Loss) On Sale Of Assets | - | 3K | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | -239K | 4.24M | -21K | -37K | -78K | |||||
EBT, Incl. Unusual Items | -19.02M | -24.81M | -32.01M | -24.95M | -18.28M | |||||
Income Tax Expense | - | - | - | 88K | 160K | |||||
Earnings From Continuing Operations | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M | |||||
Net Income to Company | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M | |||||
Minority Interest | - | - | - | - | - | |||||
Net Income - (IS) | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M | |||||
Net Income to Common Incl Extra Items | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M | |||||
Net Income to Common Excl. Extra Items | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.86 | -1 | -1.27 | -0.88 | -0.62 | |||||
Basic EPS - Continuing Operations | -0.86 | -1 | -1.27 | -0.88 | -0.62 | |||||
Basic Weighted Average Shares Outstanding | 22.04M | 24.84M | 25.15M | 28.42M | 29.64M | |||||
Net EPS - Diluted | -0.86 | -1 | -1.27 | -0.88 | -0.62 | |||||
Diluted EPS - Continuing Operations | -0.86 | -1 | -1.27 | -0.88 | -0.62 | |||||
Diluted Weighted Average Shares Outstanding | 22.04M | 24.84M | 25.15M | 28.42M | 29.64M | |||||
Normalized Basic EPS | -0.53 | -0.73 | -0.79 | -0.55 | -0.38 | |||||
Normalized Diluted EPS | -0.53 | -0.73 | -0.79 | -0.55 | -0.38 | |||||
Supplemental Items | ||||||||||
EBITDA | -14.56M | -27.2M | -23.05M | -20.05M | -10.07M | |||||
EBITA | -15.37M | -28.06M | -24.02M | -20.94M | -10.76M | |||||
EBIT | -15.37M | -28.06M | -24.02M | -20.94M | -10.76M | |||||
EBITDAR | - | - | -22.33M | -19.98M | -10.01M | |||||
Total Revenues (As Reported) | 11.78M | 8.34M | 13.66M | 11.94M | 27.73M | |||||
Effective Tax Rate - (Ratio) | - | - | - | -0.35 | -0.88 | |||||
Total Current Taxes | - | - | - | 88K | 160K | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -11.74M | -18.16M | -19.97M | -15.57M | -11.38M | |||||
Interest on Long-Term Debt | 800K | 100K | 35K | 4.51M | 5.06M | |||||
Non-Cash Pension Expense | -23K | -11K | -5K | 5K | -3K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Marketing Expenses | - | - | - | 2.31M | - | |||||
Selling and Marketing Expenses | 1.8M | 2.27M | 2.59M | 2.64M | 3.26M | |||||
General and Administrative Expenses | 5.78M | 6.21M | 7.13M | 9.15M | 10.92M | |||||
Research And Development Expense From Footnotes | 19.61M | 23.61M | 27.92M | 21.08M | 24.32M | |||||
Net Rental Expense, Total | - | - | 720K | 65K | 65K | |||||
Imputed Operating Lease Interest Expense | - | - | 431K | 39.22K | 40.08K | |||||
Imputed Operating Lease Depreciation | - | - | 289K | 25.78K | 24.92K | |||||
Stock-Based Comp., R&D Exp. (Total) | 1.12M | 1.59M | 1.41M | 1.72M | - | |||||
Stock-Based Comp., S&M Exp. (Total) | 125K | 322K | 268K | 332K | 343K | |||||
Stock-Based Comp., G&A Exp. (Total) | 318K | 485K | 601K | 760K | - | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | 2.62M | |||||
Total Stock-Based Compensation | 1.56M | 2.39M | 2.28M | 2.81M | 2.96M |
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















